Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Fingolimod Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 140,532Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enforcement Report - Week of July 26, 2023
    Enforcement Report - Week of July 26, 2023

    26 Jul 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-26-2023-55742.pdf

    FDA
    26 Jul 2023
    Share Share
    US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent
    US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent

    18 Apr 2023

    // REUTERS

    https://www.reuters.com/legal/us-supreme-court-rebuffs-novartis-bid-revive-ms-drug-gilenya-patent-2023-04-17/

    REUTERS
    18 Apr 2023
    Share Share
    Vyne swings behind BET, seeks partner for failed eczema drug
    Vyne swings behind BET, seeks partner for failed eczema drug

    10 Mar 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/vyne-swings-behind-bet-inhibitors-seeks-partner-failed-eczema-drug

    Nick Paul Taylor FIERCE BIOTECH
    10 Mar 2023
    Share Share
    Drug, TASCENSO ODT , Launched to Meet the Needs of Multiple Sclerosis Patients
    Drug, TASCENSO ODT , Launched to Meet the Needs of Multiple Sclerosis Patients

    13 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230213005286/en

    BUSINESSWIRE
    13 Feb 2023
    Share Share
    Novartis takes Gilenya patent case to Supreme Court
    Novartis takes Gilenya patent case to Supreme Court

    25 Jan 2023

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/novartis-files-supreme-court-bid-gilenya-patent-case

    FIERCE PHARMA
    25 Jan 2023
    Share Share
    Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of TASCENSO ODT (fingolimod)
    Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of TASCENSO ODT (fingolimod)

    17 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230117005777/en

    BUSINESSWIRE
    17 Jan 2023
    Share Share